Lopinavir CAS 192725-17-0 API Anti-HIV HIV Protease Inhibitor COVID-19 High Purity
Mugadziri Wekutengesa ane Kuchena Kwepamusoro uye Hunhu Hwakagadzikana
Zita reKemikari: Lopinavir
CAS: 192725-17-0
Yakanyanya Kusimba, Inosarudza Peptidomimetic HIV-1 Protease Inhibitor
COVID-19 Related Research Chigadzirwa
API High Quality, Commercial Production
Chemical Name | Lopinavir |
Mashoko anoreva zvakafanana | LPV;ABT-378;Kaletra |
Nhamba yeCAS | 192725-17-0 |
Nhamba yeCAT | RF-API73 |
Stock Status | MuStock, Kugadzirwa Kunokwira Kusvika Mazana emaKilogram |
Molecular Formula | C37H48N4O5 |
Molecular Weight | 628.81 |
Kuchengetedza Kwenguva Yakareba | Chengetedza Nguva refu pa2-8 ℃ |
Brand | Ruifu Chemical |
Item | Zvinotsanangurwa |
Chitarisiko | Ichena kusvika kuOff-White Powder |
Solubility | Yemahara Soluble muMethanol uye muEthanol, Soluble mu2-Propanol |
Kuzivikanwa IR | Iyo infrared absorption spectrum yemuyedzo sampuli inopindirana neiyo spectrum yereferensi chiyero. |
Kuzivikanwa HPLC | Nguva yekuchengeta yemuenzaniso webvunzo inoenderana neiyo yereferensi mwero |
Mvura Yemukati (neKF) | ≤4.0% |
Specific Optical Rotation | -22.0° kusvika -26.0° |
Residue paIgnition | ≤0.20% |
Heavy Metals | ≤20ppm |
Melting Point | 124.0 kusvika 127.0 ℃ |
Sulfated Ash | ≤0.20% |
Residual Solvent (Ethanol) | ≤0.50% |
Related Substances | (HPLC, Nzvimbo%) |
Kusachena 1 | |
Kusachena B (RRT=0.07) | ≤0.20% |
Kusachena I (RRT=1.10) | ≤0.20% |
Chero Kumwe Kusachena | ≤0.10% |
Kusachena 2 | Chero Kumwe Kusachena Kwemunhu ≤0.10% |
Yese Kusachena kubva muKutaridza 1 uye 2 | ≤0.70% |
Zvose Zvisina Kuchena | ≤1.0% |
Assay (neHPLC) | 98.0%~102.0% |
Test Standard | Enterprise Standard |
Usage | Sarudza Peptidomimetic HIV-1 Protease Inhibitor, COVID-19 Inoenderana Netsvagiridzo Chigadzirwa |
Package: Bhodhoro, Aluminium foil bag, Cardboard dhiramu, 25kg/Drum, kana zvinoenderana nezvinodiwa nemutengi.
Storage Condition:Chengetedza mumidziyo yakavharwa panzvimbo inotonhorera uye yakaoma;Dzivirira kubva kuchiedza, mwando uye tumbuyu.
Lopinavir (ABT-378) ine simba zvakanyanya, inosarudza peptidomimetic inhibitor yeHIV-1 protease, ine Kis ye1.3 kusvika 3.6 pM yemhando yemusango uye mutant HIV protease.Lopinavir inoita nekusunga kukura kweHIV-1 nekudaro ichivharira kusatapukira kwayo.Lopinavir zvakare iri SARS-CoV 3CLpro inhibitor ine IC50 ye14.2 μM.Lopinavir iantiretroviral yekirasi yeprotease inhibitor.Kuvharirwa kweHIV-1 protease kunodzivirira kutsemuka kwehutachiwana hwepolyprotein precursor uye kunoguma nekuburitswa kwemavirioni asina kusimba, asina kutapuriranwa.Chikamu chemusanganiswa kurapa kurapa HIV/AIDS.Lopinavir, yechitanhatu HIV protease inhibitor mukirasi ye “navir”, yakatangwa mukubatana ne ritonavir, imwe HIV protease inhibitor yatotengeswa (Abbott, 1996);kuumbwa kwepakutanga uku kwakaunzwa seKaletra kuti ishandiswe pamwe chete nenucleoside kana kuti non-nucleoside reverse transcriptase inhibitors yekurapa AIDS muvakuru nevana.Lopinavir mukomboni wepeptidomimetic une musimboti wakafanana nereritonavir, apo mapoka ekupedzisira, kunyanya yakagadziridzwa valine, akaunzwa nepeptide coupling maitiro.Lopinavir inhibitor ine simba inokwikwidza yeHIV-I protease inoratidza kugona kwakanyanya kupesana ne ritonavir-resistant mutations.Mumarudzi akati wandei emhuka, zvidzidzo zvepharmacokinetic pamwe nesangano relopinavirlritonavir zvakaratidza kuti zvimiro zvine mwero zvelopinavir zvakavandudzwa zvakanyanya pamberi pe ritonavir, maererano neCmax uye nguva yekuita.